Furthermore, the mechanism by which SARS-CoV-2 directly induces NET formation has been progressively elucidated, with both the neutralizing anti-hACE2 antibody (aACE2) targeting the ACE2 receptor and the TMPRSS2 inhibitor camostat proven to eliminate SARS-CoV-2-induced NETs as well as reduce viral load within SARS-CoV-2-exposed neutrophils, positioning these agents as promising candidates for alleviating COVID-19-associated AKI (123). Here, TMPRSS2 is linked to COVID-19.